Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q3 2023 · 10-Q
Revenue$13.12M$13.12M+78.2% vs Q3 2022 Net Income-$8.08M-$8.08MN/M vs Q3 2022 EPS Diluted-$2.10-$2.10N/M vs Q3 2022 Operating Income-$12,363,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$23,479,000N/M Margins · derivedOperating margin-94.2%+105.1 pt vs Q3 2022
Net margin-61.6%+263.6 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 7, 2023 · 38 d after period end